Beijing-based biotech Immunochina Pharmaceuticals has reportedly raised “hundreds of millions” of renminbi in a Series E financing round. The round was led by BTH Coordinated Development Industrial Investment Fund, with contributions from Taiping Medical and Health Industry Equity Investment Fund, Beijing Science and Technology Innovation Group, Beijing Sun-Novo Pharmaceutical Research Co., Ltd., and more.
Use of Proceeds
The proceeds will be used to support the commercial layout of Immunochina’s IM19, a chimeric antigen receptor (CAR)-T therapy for advanced lymphoma. Additionally, funds will be allocated to ramp up research and development and the clinical process of new products targeting blood cancer, solid tumors, and autoimmune diseases. The company also plans to facilitate the construction of universal CAR-T and gene editing technology platforms, positioning itself at the forefront of next-generation gene cell therapies.
Company Overview
Immunochina, a commercial-stage gene therapy specialist, has completed 10 strategic financing rounds since its inception in 2015. The company’s product pipeline covers a range of hematological tumors, including lymphoma, leukemia, and myeloma, as well as solid tumors such as liver cancer, colorectal cancer, and melanoma. This latest funding round underscores Immunochina’s commitment to advancing innovative therapies and expanding its market presence in the gene therapy sector.-Fineline Info & Tech
